ClinicalTrials.gg
CompletedNCT00547599Updated Oct 22, 2007

Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects

A Phase 4 interventional study of tadalafil in Impotence, sponsored by Eli Lilly and Company. Completed at 1 site in Sweden. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-10-22.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
659
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
6th of 56
659 · median 199
Started
2003
with 7 others
Phase 4
26 of 57
3 open now
Registered
11th of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 6th largest by enrollment of the 56 interventional ones that give a count, is one of 8 that started in 2003, is one of 26 in phase 4, and was the 11th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

To determine if patients who are distressed over having problems getting or maintaining an erection react differently to the medication than those who are not stressed over the issue.

03

Conditions studied

  • Impotence

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 3 months history of erectile dysfunction (ED)
  • Anticipate a monogamous relationship with a female sexual partner
  • Be able to make minimum required sexual intercourse attempts
  • Abstain from using any other ED treatment

Exclusion criteria

Exclusion Criteria:

  • Nitrate use
  • Participated in previous tadalafil study or have a current tadalafil prescription
  • Heart attack within the last 90 days
  • Kidney problems
  • Certain heart problems
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
659 participants (actual)

Study arms

  • Active comparator
    1

    20 mg tadalafil tablet

    Drug: tadalafil

Interventions

  • 20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.

    Also known as: LY450190, Cialis, IC351

06

What researchers measure

Primary outcomes

  1. Change In Spontaneity Domain of PAIRS scale scores

    Time frame: 8 weeks

Secondary outcomes

  1. Change in the Time Concerns, Sexual Self-Confidence & Sexual Miscommunication, domains of PAIRS scale scores

    Time frame: 8 weeks

07

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Uppsala, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2007
First posted
Oct 22, 2007
Start
Apr 2003
CompletionActual
Jan 2004
Last update
Oct 22, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00547599
Collaborators
ICOS Corporation
First posted
Oct 22, 2007
Start date
Apr 2003
Completion
Jan 2004
Last update
Oct 22, 2007

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion